Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for CytomX Therapeutics (CTMX) over the last 10 years, with Q3 2025 value amounting to $46.6 million.

  • CytomX Therapeutics' Total Non-Current Liabilities fell 7059.86% to $46.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $46.6 million, marking a year-over-year decrease of 7059.86%. This contributed to the annual value of $116.9 million for FY2024, which is 5236.36% down from last year.
  • Per CytomX Therapeutics' latest filing, its Total Non-Current Liabilities stood at $46.6 million for Q3 2025, which was down 7059.86% from $50.9 million recorded in Q2 2025.
  • CytomX Therapeutics' Total Non-Current Liabilities' 5-year high stood at $346.6 million during Q4 2022, with a 5-year trough of $46.6 million in Q3 2025.
  • Over the past 4 years, CytomX Therapeutics' median Total Non-Current Liabilities value was $199.4 million (recorded in 2024), while the average stood at $192.6 million.
  • In the last 5 years, CytomX Therapeutics' Total Non-Current Liabilities plummeted by 655.61% in 2023 and then crashed by 7269.77% in 2025.
  • CytomX Therapeutics' Total Non-Current Liabilities (Quarter) stood at $346.6 million in 2022, then dropped by 29.22% to $245.3 million in 2023, then plummeted by 52.36% to $116.9 million in 2024, then crashed by 60.16% to $46.6 million in 2025.
  • Its Total Non-Current Liabilities stands at $46.6 million for Q3 2025, versus $50.9 million for Q2 2025 and $69.3 million for Q1 2025.